NCT05933317

Brief Summary

So far, the number of COVID-19 infections worldwide has exceeded 700 million. Long-term damage to the lungs is a major sequela of COVID infection. Pulmonary function testing is an important means for the evaluation of lung damage. MRI examinations with free breathing and no contrast agent can prevent patients from suffering from ionizing radiation damage caused by multiple CT examinations.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2023

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

July 5, 2023

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 6, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

July 6, 2023

Status Verified

July 1, 2023

Enrollment Period

12 months

First QC Date

July 5, 2023

Last Update Submit

July 5, 2023

Conditions

Pulmonary Function

Outcome Measures

Primary Outcomes (1)

  • QDP, VDP

    perfusion defect percentage, ventilation defect percentage

    6 months

Interventions

Functional lung MRIDIAGNOSTIC_TEST

Functional lung MRI

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Inpatients and outpatients with COVID-19

You may qualify if:

  • Older than 18 years; Sign the informed consent; Patients diagnosed with COVID-19 by nucleic acid test and survived to be discharged; Complete clinical data during hospitalization.

You may not qualify if:

  • Patients with bacterial pneumonia; Patients with MRI contraindications.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beijing Chaoyang Hospital

Beijing, Beijing Municipality, 100020, China

RECRUITING

Study Officials

  • Tao Ouyang, Dr.

    Beijing Chao Yang Hospital

    STUDY CHAIR

Central Study Contacts

Tao Ouyang, Dr.

CONTACT

+86 18720931226ouyt1996@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Beijing Chao Yang Hospital

Study Record Dates

First Submitted

July 5, 2023

First Posted

July 6, 2023

Study Start

January 1, 2023

Primary Completion

December 31, 2023

Study Completion

December 31, 2024

Last Updated

July 6, 2023

Record last verified: 2023-07

Locations

CN(1)